The Cardiff firm’s technology is designed to deliver high molecular weight drugs through the skin without some of the dose-reproducibility problems associated with other microneedle and poration techniques.
The Ocelus approach is to injects small drug containing particles into the skin at hundreds of sites per sqcm. These particle then dissolve over time steadily releasing their contents in a predictable manner.
The funding is made up of a £315,000 equity investment from Finance Wales and a £147,000 is a grant from the Welsh Assembly.
Founder Andrew Kirby said that: “With this funding, we are able to continue development on our innovative system and work with leading micro-engineering, and pharmaceutical formulation companies from around the world to produce optimized prototypes for testing in human skin.”